Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Exelixis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For All Participants
* Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective.
* For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies.
Expansion Stage
* Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra).
* At least one measurable lesion as defined by RECIST, version 1.1.
* Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy.
At least one but no more than 3 prior lines of therapy.
Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo)
You may not be if
Prior anticancer treatment, including:
* Radiation therapy within 2 weeks before first dose of study treatment.
Known brain metastases or cranial epidural disease
Current or recent severe illness
Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria.
Active infection with hepatitis B virus or hepatitis C virus.
Malabsorption syndrome.
History of solid organ, autologous or allogenic stem cell transplant.
Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy.
